$2.85 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 114 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SCYX | Exit | SCYNEXIS INC | $0 | – | -1,020,000 | -100.0% | -0.05% | – |
| OBLN | Exit | OBALON THERAPEUTICS INC | $0 | – | -446,284 | -100.0% | -0.05% | – |
| EGLTQ | Exit | EGALET CORP | $0 | – | -3,239,237 | -100.0% | -0.07% | – |
| ADVM | Exit | ADVERUM BIOTECHNOLOGIES INC | $0 | – | -422,000 | -100.0% | -0.08% | – |
| TSRO | Exit | TESARO INC | $0 | – | -42,893 | -100.0% | -0.08% | – |
| IFRX | Exit | INFLARX NV | $0 | – | -88,500 | -100.0% | -0.09% | – |
| TCMD | Exit | TACTILE SYS TECHNOLOGY INC | $0 | – | -91,020 | -100.0% | -0.10% | – |
| ARMO | Exit | ARMO BIOSCIENCES INC | $0 | – | -188,525 | -100.0% | -0.24% | – |
| Exit | ALLSCRIPTS HEALTHCARE SOLUTNnote 1.250% 7/0 | $0 | – | -9,671,000 | -100.0% | -0.34% | – | |
| Exit | EXACT SCIENCES CORPdbcv 1.000% 1/1 | $0 | – | -12,500,000 | -100.0% | -0.38% | – | |
| REPH | Exit | RECRO PHARMA INC | $0 | – | -1,010,000 | -100.0% | -0.38% | – |
| PODD | Exit | INSULET CORP | $0 | – | -171,000 | -100.0% | -0.51% | – |
| MNLO | Exit | MENLO THERAPEUTICS INC | $0 | – | -426,749 | -100.0% | -0.56% | – |
| PTLA | Exit | PORTOLA PHARMACEUTICALS INCcall | $0 | – | -500,000 | -100.0% | -0.57% | – |
| PTLA | Exit | PORTOLA PHARMACEUTICALS INCput | $0 | – | -500,000 | -100.0% | -0.57% | – |
| MCK | Exit | MCKESSON CORP | $0 | – | -150,000 | -100.0% | -0.73% | – |
| CBIO | Exit | CATALYST BIOSCIENCES INC | $0 | – | -830,605 | -100.0% | -0.74% | – |
| GSK | Exit | GLAXOSMITHKLINE PLCsponsored adr | $0 | – | -810,000 | -100.0% | -1.10% | – |
| DVA | Exit | DAVITA INC | $0 | – | -486,427 | -100.0% | -1.11% | – |
| Exit | ISIS PHARMACEUTICALS INC DELnote 1.000%11/1 | $0 | – | -45,700,000 | -100.0% | -1.57% | – | |
| AVXS | Exit | AVEXIS INC | $0 | – | -755,798 | -100.0% | -3.24% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
| 13F-HR | 2023-11-14 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.